WallStSmart

Lineage, Inc. Common Stock (LINE)vsQuipt Home Medical Corp (QIPT)

VS

Smart Verdict

WallStSmart Research — data-driven comparison

Lineage, Inc. Common Stock generates 1921% more annual revenue ($5.36B vs $264.97M). LINE leads profitability with a -1.9% profit margin vs -4.0%. QIPT earns a higher WallStSmart Score of 40/100 (D).

LINE

Hold

36

out of 100

Grade: F

Growth: 3.3Profit: 3.5Value: 5.0Quality: 3.8
Piotroski: 5/9Altman Z: 0.81

QIPT

Hold

40

out of 100

Grade: D

Growth: 7.3Profit: 2.5Value: 5.0Quality: 5.0

Key Strengths & Concerns

Side-by-side fundamental analysis

Key Strengths

LINE1 strengths · Avg: 10.0/10
Price/BookValuation
1.0x10/10

Reasonable price relative to book value

QIPT2 strengths · Avg: 9.0/10
Revenue GrowthGrowth
32.0%10/10

Revenue surging 32.0% year-over-year

Price/BookValuation
1.6x8/10

Reasonable price relative to book value

Areas to Watch

LINE4 concerns · Avg: 2.5/10
EPS GrowthGrowth
0.0%4/10

0.0% earnings growth

Return on EquityProfitability
-1.2%2/10

ROE of -1.2% — below average capital efficiency

Revenue GrowthGrowth
-0.2%2/10

Revenue declined 0.2%

Altman Z-ScoreHealth
0.812/10

Distress zone — elevated risk

QIPT4 concerns · Avg: 2.5/10
Market CapQuality
$162.30M3/10

Smaller company, higher risk/reward

Operating MarginProfitability
1.5%3/10

Operating margin of 1.5%

Return on EquityProfitability
-9.3%2/10

ROE of -9.3% — below average capital efficiency

EPS GrowthGrowth
-97.7%2/10

Earnings declined 97.7%

Comparative Analysis Report

WallStSmart Research

Bull Case : LINE

The strongest argument for LINE centers on Price/Book.

Bull Case : QIPT

The strongest argument for QIPT centers on Revenue Growth, Price/Book. Revenue growth of 32.0% demonstrates continued momentum.

Bear Case : LINE

The primary concerns for LINE are EPS Growth, Return on Equity, Revenue Growth.

Bear Case : QIPT

The primary concerns for QIPT are Market Cap, Operating Margin, Return on Equity.

Key Dynamics to Monitor

LINE profiles as a turnaround stock while QIPT is a hypergrowth play — different risk/reward profiles.

QIPT is growing revenue faster at 32.0% — sustainability is the question.

LINE generates stronger free cash flow (78M), providing more financial flexibility.

Monitor REIT - INDUSTRIAL industry trends, competitive dynamics, and regulatory changes.

Bottom Line

QIPT scores higher overall (40/100 vs 36/100) and 32.0% revenue growth. Both earn "Hold" and "Hold" ratings respectively — the choice depends on your investment horizon and risk tolerance.

This analysis is generated from publicly available financial data. Not financial advice.

Lineage, Inc. Common Stock

REAL ESTATE · REIT - INDUSTRIAL · USA

Lineage, Inc. (Ticker: LINE) is an innovative biotechnology company at the forefront of regenerative medicine, specializing in the development of advanced cell therapy solutions aimed at treating severe diseases such as eye disorders, spinal cord injuries, and cancer. Leveraging proprietary technologies and a strong commitment to strategic partnerships, the company is dedicated to revolutionizing patient care with its novel therapeutic approaches. As Lineage continues to enhance its diverse product pipeline and accelerate clinical research initiatives, it represents a compelling opportunity for institutional investors looking to support transformative advancements in healthcare.

Visit Website →

Quipt Home Medical Corp

HEALTHCARE · MEDICAL DISTRIBUTION · USA

Quipt Home Medical Corp. The company is headquartered in Wilder, Kentucky.

Want to dig deeper into these stocks?